Title :

Predictive factors of stent patency in iliofemoral venous diseases in a multicenter cohort study.

Author(s) :

Espitia, Olivier [Auteur]
Centre hospitalier universitaire de Nantes [CHU Nantes]
Douane, Frédéric [Auteur]
Centre hospitalier universitaire de Nantes [CHU Nantes]
Hersant, Jeanne [Auteur]
Centre Hospitalier Universitaire d'Angers [CHU Angers]
Abbadie, Fabrice [Auteur]
Sobocinski, Jonathan [Auteur]
Advanced Drug Delivery Systems (ADDS) - U1008
Heautot, Jean-François [Auteur]
Service de radiologie et imagerie médicale [Rennes] = Radiology [Rennes]
Miossec, Annaïg [Auteur]
Centre hospitalier universitaire de Nantes [CHU Nantes]
Lapébie, François Xavier [Auteur]
Service de Médecine Vasculaire [CHU Toulouse]
Hartung, Olivier [Auteur]
CHU Marseille

Journal title :

European Journal of Vascular and Endovascular Surgery

Abbreviated title :

Eur J Vasc Endovasc Surg

Publisher :

Elsevier

Publication date :

2023-01-20

ISSN :

1532-2165

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Objective This study assessed primary stent patency predictive factors in three groups of patients with history of lower limb (LL) vein thrombosis: non-thrombotic iliac vein lesion (NIVL), acute deep vein thrombosis (aDVT), ...
Show more >Objective This study assessed primary stent patency predictive factors in three groups of patients with history of lower limb (LL) vein thrombosis: non-thrombotic iliac vein lesion (NIVL), acute deep vein thrombosis (aDVT), and post-thrombotic syndrome (PTS). Methods Consecutive patients from January 2014 to December 2020 with history of LL vein stenting from seven hospitals were included. All patients received an iliac or common femoral venous stent and had at least a six month follow up available with stent imaging. Anticoagulant and antiplatelet therapy strategies employed after venous stenting are reported and compared between groups. Results This study included 377 patients: 134 NIVL, 55 aDVT, and 188 PTS. Primary patency was statistically significantly higher in the NIVL group (99.3%) compared with the PTS group (68.6%) (p < .001) and the aDVT group (83.6%) (p = .002). PTS patients received a statistically significantly greater number of stents (p < .001) and had more stents below the inguinal ligament (p < .001). Median follow up was 28.8 months (IQR 16, 47). Discontinuation of antiplatelet therapy at the last assessment was 83.6% for NIVL, 100% for aDVT, and 95.7% for the PTS group (p < .001). Discontinuation of anticoagulation therapy at the last assessment was 93.2% for NIVL, 25.0% for aDVT, and 70.3% for the PTS group (p < .001). The only predictor of worse primary patency in the aDVT group was long term anticoagulation before stenting. Conclusion Patients with NIVL have better primary patency after venous stenting than patients with venous thrombotic disorders. Long term anticoagulation before stenting was the only factor associated with poorer primary patency in patients with aDVT.Show less >

Language :

Anglais

Audience :

Internationale

Administrative institution(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Advanced Drug Delivery Systems (ADDS) - U1008

Submission date :

2023-02-28T00:54:39Z
2023-03-08T07:30:14Z